Description:
Mantle Cell Lymphoma is a rare subtype of B-cell non-Hodgkin Lymphoma characterized by disease heterogeneity.  The approach to treating patients diagnosed with mantle cell lymphoma has evolved over time with therapeutics including high dose cytarabine containing regimens prior to autologous stem cell consolidation, rituximab maintenance and the oral Bruton’s tyrosine kinase inhibitors for relapsed/refractory disease.  It is recognized that not all patients benefit from these approaches.  This educational session will explore the evolving treatment landscape in mantle cell lymphoma including identification and treatment of patients with high-risk disease, the role of autologous stem cell transplant consolidation in the era of novel therapies and the current and future incorporation of T-cell engaging therapies in the treatment landscape.

Dr. Kami Maddocks will define high-risk features in Mantle Cell Lymphoma associated with inferior prognosis to standard treatment approaches. Clinical trials incorporating Bruton's tyrosine kinase inhibitors into initial therapy will be discussed. The role of targeted and immunotherapy combinations in a “chemotherapy-free” approach will be presented.

Dr. Martin Dreyling will discuss the role of autologous stem cell transplantation and additional consolidation/maintenance therapies in first line treatment. Clinical trials incorporating Bruton's tyrosine kinase inhibitors into initial therapy will be mentioned. Differential treatment strategies according to clinically applicable biological risk factors will be suggested.

Dr. Lia Palomba will review T-cell engaging therapies in relapsed or refractory Mantle Cell Lymphoma, including CAR T-cells and bispecific antibodies. She will review available data on the outcome of these therapies in the general MCL population and in high-risk subgroups.